drugset / Trial / NCT05561816

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

NCT05561816

Phase 3 Completed 240 enrolled Valenta Pharm JSC
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is aimed to: * evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, * evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

Timeline

Start
2022-07-19
Primary completion
2022-11-28
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium Small molecule 0.01 % Topical
Subject DIOXYDINE Small molecule 0.025 % Topical

Indications